Printer Friendly

ivWatch raises USD14.8m from funding round.

M2 PHARMA-June 8, 2017-ivWatch raises USD14.8m from funding round

(C)2017 M2 COMMUNICATIONS

ivWatch LLC stated on Wednesday that it has closed its latest funding round of USD14.8m with undisclosed angel investors, family funds and a major hospital system.

According to the company, the financing will be used to support the direct go-to-market initiatives and strategic partner activities. The funds will be used to deliver more of its new IV therapy technologies to market.

The company added it offers a first of its kind solution for continuously monitoring an IV site to assess if drugs are actually being delivered to the vein without leakage.

In addition, the company's technology is the first of its kind to offer a solution for continuously monitoring an IV site and assessing if drugs are actually being delivered to the vein without leakage. The ivWatch Model 400 is an FDA-cleared device that continuously monitors any patient's peripheral IV for the early detection of these infiltration and extravasation events and helps clinicians manage the risk associated with IV therapy.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 8, 2017
Words:186
Previous Article:Eleven Biotherapeutics signs cooperative research and development agreement with National Cancer Institute.
Next Article:US FDA approves Alkermes's Aristada two-month dosing option.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters